Contents

Part I  Overview

1   Historical Perspectives and Current Trends in Cancer Immunotherapy ........................................ 3
    Tyler J. Curiel

2   T Cell and Antigen-Presenting Cell Subsets in the Tumor Microenvironment .............................. 17
    Cailin Moira Wilke, Shuang Wei, Lin Wang, Ilona Kryczek, Jingyuan Fang, Guobin Wang, and Weiping Zou

Part II  Passive Strategies to Boost Antitumor Immunity

3   Adoptive T Cell Transfer ........................................ 47
    Donald R. Shaffer, Conrad Russell Y. Cruz, and Cliona M. Rooney

4   Dendritic Cell-Based Cancer Immunotherapy: Achievements and Novel Concepts ....................... 71

Part III  Active Strategies to Boost Antitumor Immunity

5   Peptide and Protein-Based Cancer Vaccines ........................................ 111
    Marion Braun, Rachel Perret, Godehard Scholz, and Pedro Romero

6   Antigen Targeting to Dendritic Cells for Cancer Immunotherapy ........................................ 147
    Dinja Oosterhoff, David T. Curiel, and Tanja D. de Gruijl

7   Cytokines in the Treatment of Cancer ........................................ 173
    Kim Margolin, Mark Lazarus, and Howard L. Kaufman
8 Immune Co-signaling to Treat Cancer ........................................ 211
Margaret K. Callahan, Jedd D. Wolchok, James P. Allison, and Padmanee Sharma

9 Managing Regulatory T Cells to Improve Cancer Immunotherapy ........................................ 281
Tyler J. Curiel

10 Myeloid-Derived Suppressor Cells in Cancer: Mechanisms and Therapeutic Perspectives ........................................ 315
Paulo C. Rodríguez and Augusto C. Ochoa

11 Antibodies as Cancer Immunotherapy ........................................ 335
Devalingam Mahalingam and Tyler J. Curiel

12 Targeted Toxins in Cancer Immunotherapy ........................................ 377
Devalingam Mahalingam, Michael J. Brumlik, Reinhard Waehler, David T. Curiel, and Tyler J. Curiel

Part IV Additional Strategies and Considerations

13 Miscellaneous Approaches and Considerations: TLR Agonists and Other Inflammatory Agents, Anti-Chemokine Agents, Infectious Agents, Tumor Stroma Targeting, Age and Sex Effects, and Miscellaneous Small Molecules ........................................ 399
Robert S. Svatek and Tyler J. Curiel

14 Monitoring Antigen-Specific Responses in Clinical Trials of Cancer Immunotherapy ........................................ 425
Audi G. Chapuis and Cassian Yee

15 Issues in Pre-clinical Models, Clinical Trial Design and Analytical Considerations in Developing and Evaluating Novel Cancer Immunotherapies ........................................ 455
Marijo Bilusic, Ravi A. Madan, and James L. Gulley

Abbreviations ........................................ 475
Index ........................................ 477
Cancer Immunotherapy
Paradigms, Practice and Promise
Curiel, T.J. (Ed.)
2013, X, 486 p., Hardcover